NCT06599619 2026-01-26
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
University of Pittsburgh
Recruiting
Clinical Trials
14 trialsNCT07223411 2025-11-26
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
University of Pittsburgh
Recruiting
NCT07091695 2025-11-12
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Bristol-Myers Squibb
Completed
NCT07092670 2025-09-05
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Intergruppo Melanoma Italiano
Recruiting
NCT04146324 2025-01-24
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
Bristol-Myers Squibb
Completed
NCT06627595 2024-11-15
APiTOXMM
University Hospital, Montpellier
Recruiting
NCT06163170 2024-04-18
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
Bristol-Myers Squibb
Completed
NCT05611229 2023-04-06
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
Novartis
Completed
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT05714371 2023-02-06
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
Novartis
Completed
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown
NCT04136470 2020-08-10
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
Ardigen
Unknown
NCT04169867 2019-11-20
Polish Microbiome Map
Ardigen
Unknown
NCT03165409 2017-10-05
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
Bristol-Myers Squibb
Completed